HomeMarket NewsCALT Stock Earnings: Calliditas Therapeutics Misses EPS, Misses Revenue for Q1 2024

CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Misses Revenue for Q1 2024

By Ron Finklestien
Today's Market Recap

Daily Market Recaps (no fluff)

always free

CALT stock - CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Misses Revenue for Q1 2024

Source: iQoncept / Shutterstock

Calliditas Therapeutics (NASDAQ:CALT) just reported results for the first quarter of 2024.

  • Calliditas Therapeutics reported earnings per share of -88 cents. This was below the analyst estimate for EPS of -14 cents.
  • The company reported revenue of $28.43 million.
  • This was 18.07% worse than the analyst estimate for revenue of $34.70 million.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/calt-stock-earnings-calliditas-therapeutics-for-q1-of-2024/.

©2024 InvestorPlace Media, LLC

Do you want a daily market summary with no fluff?

Simple Straightforward Daily Stock Market Recaps Sent for free,every single trading day: Read Now

Explore More

Simple Straightforward Daily Stock Market Recaps

Get institutional-level analysis to take your trading to the next level, sign up for free and become apart of the community.

Read Now

Related Articles

spot_img

WallStreet Waves

Comprehensive stock market news coverage across various asset classes, including stocks, bonds, commodities, cryptocurrencies, and more. We believe in offering a holistic perspective, allowing our readers to stay ahead of the stock market and capitalize on emerging opportunities in tech stocks, small caps, biotechs and more!

most Popular

trending right now

© 2024 All Rights reserved | Powered by WallStreet Waves